title: ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
abstract: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo.
  
  
  
  During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners' Parent Rating Scale-Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria.
  
  
  
  Most participants given LDX ( n = 207) were responders throughout the day (50.7%-55.6%) versus placebo ( n = 72; 11.1%-22.2%). A total of seven (3.4%) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7%) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9).
  
  
  
  ADHD symptom rebound occurred in few participants (3.3%) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day.
authors: 1 Children's Developmental Center, Winter Park, FL, USA.
authors: Frank A
authors: FA
authors: López
authors: 2 Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA.
authors: Ann
authors: A
authors: Childress
authors: 3 Shire Development LLC, Wayne, PA, USA.
authors: Ben
authors: B
authors: Adeyi
authors: 3 Shire Development LLC, Wayne, PA, USA.
authors: Bryan
authors: B
authors: Dirks
authors: 3 Shire Development LLC, Wayne, PA, USA.
authors: Thomas
authors: T
authors: Babcock
authors: 3 Shire Development LLC, Wayne, PA, USA.
authors: Brian
authors: B
authors: Scheckner
authors: 4 Pharmanet/i3, an inVentiv Health clinical, Princeton, NJ, USA.
authors: Robert A
authors: RA
authors: Lasser
authors: 3 Shire Development LLC, Wayne, PA, USA.
authors: John
authors: J
authors: Shepski
authors: 5 University of Tennessee, Memphis, TN, USA.
authors: Valerie
authors: V
authors: Arnold
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D002648:Child; D003913:Dextroamphetamine / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004644:Emotions / Q000187:drug effects; D005260:Female; D006801:Humans; D000069478:Lisdexamfetamine Dimesylate / Q000008:administration & dosage*; D008297:Male; D019964:Mood Disorders / Q000188:drug therapy*; D010290:Parents / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D000069478:Lisdexamfetamine Dimesylate; D003913:Dextroamphetamine
keywords: ADHD; emotional lability; lisdexamfetamine dimesylate; symptom rebound